VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PETS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PETSPetMed Express, Inc.
$1.82$39M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPETSFinancials

PetMed Express, Inc. (PETS) Financials

27Y historyFree accessUpdated daily

Revenue growth has contracted significantly, with the company reporting a 2026Q4 revenue of $42.8M and a negative operating margin of -13.3%.

PETS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00
Sales/Revenue179.02M226.97M274.1M256.58M273.42M303.58M284.13M283.42M273.8M249.18M234.68M229.4M233.39M227.83M238.25M231.64M238.27M219.41M188.34M162.25M137.58M108.36M93.99M54.97M32.03M10.01M14.68M
Revenue Growth %-21.13%-17.19%6.83%-6.16%-9.94%6.85%0.25%3.51%9.88%6.18%2.31%-1.71%2.44%-4.37%2.85%-2.78%8.59%16.5%16.08%17.93%26.97%15.28%70.98%71.66%220.06%-31.82%-
Cost of Goods Sold128.81M157.84M196.38M185.84M198.08M219.27M202.88M188.1M175.99M169.86M158.39M153.13M155.77M150.71M158.09M147.69M146.41M134.08M114.12M97.68M83.24M64.7M55.82M31.52M18.89M6.37M9.06M
COGS % of Revenue71.95%69.54%71.65%72.43%72.45%72.23%71.4%66.37%64.28%68.17%67.49%66.75%66.74%66.15%66.35%63.76%61.45%61.11%60.59%60.2%60.5%59.71%59.39%57.33%59%63.64%61.74%
Gross Profit50.22M69.14M77.71M71.01M75.34M84.32M81.25M95.31M97.81M79.31M76.3M76.27M77.62M77.12M80.17M83.96M91.86M85.33M74.21M64.57M54.34M43.66M38.17M23.46M13.13M3.64M5.62M
Gross Margin %28.05%30.46%28.35%27.68%27.55%27.77%28.6%33.63%35.72%31.83%32.51%33.25%33.26%33.85%33.65%36.24%38.55%38.89%39.41%39.8%39.5%40.29%40.61%42.67%41%36.36%38.26%
Gross Profit Growth %-27.37%-11.03%9.43%-5.74%-10.65%3.78%-14.76%-2.55%23.32%3.96%0.03%-1.74%0.64%-3.8%-4.52%-8.61%7.66%14.97%14.94%18.82%24.47%14.38%62.72%78.63%260.88%-35.2%-
Operating Expenses72.24M70.67M84.67M64.68M49.63M53.78M50.27M49.14M45.67M41.83M43.91M46.94M49.4M50.12M54.14M50.93M51.32M51.13M46.22M43.07M36.19M31.16M28.96M19.97M12.38M6.28M7.2M
OpEx % of Revenue40.36%31.13%30.89%25.21%18.15%17.72%17.69%17.34%16.68%16.79%18.71%20.46%21.17%22%22.73%21.99%21.54%23.3%24.54%26.54%26.31%28.75%30.81%36.33%38.67%62.74%49.06%
Selling, General & Admin72.24M62.43M79.75M68.9M49.63M49.93M48.01M46.91M43.55M40.46M43.14M46.28M48.53M49.02M52.73M49.56M50M50.31M45.63M42.54M35.65M30.58M28.41M19.61M11.81M5.9M7.37M
SG&A % of Revenue40.36%27.5%29.1%26.85%18.15%16.45%16.9%16.55%15.9%16.24%18.38%20.18%20.79%21.52%22.13%21.39%20.98%22.93%24.23%26.22%25.91%28.22%30.22%35.66%36.88%59%50.22%
Research & Development000000000000000000000000000
R&D % of Revenue---------------------------
Other Operating Expenses08.24M4.92M-4.21M03.85M2.26M2.23M2.13M1.37M770K2.37M867K1.09M1.41M1.38M1.32M814.54K589.99K530.44K544.53K573.82K550.39K367.67K571.76K373.85K-169.98K
Operating Income-31.41M-1.53M-6.96M6.55M25.71M30.53M30.98M46.17M52.14M37.48M32.39M27.61M28.22M27M26.02M33.02M40.54M34.2M28M21.5M18.15M12.5M9.21M3.48M747.94K-2.64M-1.59M
Operating Margin %-17.55%-0.67%-2.54%2.55%9.4%10.06%10.9%16.29%19.04%15.04%13.8%12.04%12.09%11.85%10.92%14.26%17.02%15.59%14.86%13.25%13.19%11.54%9.8%6.34%2.34%-26.37%-10.8%
Operating Income Growth %-1953.27%78.02%-206.27%-74.52%-15.79%-1.44%-32.91%-11.44%39.09%15.73%17.29%-2.14%4.49%3.78%-21.2%-18.54%18.54%22.17%30.21%18.49%45.14%35.72%164.47%365.68%128.34%-66.45%-
EBITDA-22.03M5.51M94K10.1M28.45M32.96M33.23M48.4M54.26M38.85M33.16M28.27M29.09M28.1M27.43M34.4M41.86M35.02M28.59M22.03M18.69M13.08M9.76M3.85M984.65K-2.73M-1.76M
EBITDA Margin %-12.3%2.43%0.03%3.94%10.4%10.86%11.7%17.08%19.82%15.59%14.13%12.32%12.46%12.33%11.51%14.85%17.57%15.96%15.18%13.58%13.58%12.07%10.39%7%3.07%-27.26%-11.96%
EBITDA Growth %-499.85%5760.64%-99.07%-64.51%-13.68%-0.83%-31.33%-10.8%39.66%17.17%17.28%-2.79%3.52%2.42%-20.25%-17.83%19.56%22.49%29.75%17.87%42.94%33.95%153.51%291.07%136.1%-55.36%-
D&A (Non-Cash Add-back)9.39M7.04M7.06M3.55M2.74M2.43M2.26M2.23M2.13M1.37M770K660K867K1.09M1.41M1.38M1.32M814.54K589.99K530.44K544.53K573.82K550.39K367.67K236.72K-88.29K-169.98K
EBIT-31.41M-330K-6.27M7.45M27.07M30.53M33.89M49.12M53.79M37.92M32.39M29.33M28.4M27.31M26.02M33.02M40.54M34.2M28M21.5M18.15M12.5M9.21M3.48M747.94K-2.64M-1.59M
Net Interest Income511K0511K450K335K-896K1.75M1.86M658K141K190K184K185K306K288K381K196K1.06M1.77M00000000
Interest Income511K0511K450K335K314K1.75M1.86M658K141K190K184K185K306K288K381K196K1.06M1.77M00000000
Interest Expense000001.21M000000000000000002.6K0187.61K14.35K
Other Income/Expense-25.94M943K689K894K1.36M419K2.92M2.95M1.65M441K179K185K181K301K349K253K200K1.46M2.42M1.7M889.95K101.79K2.13K-2.6K77.47K-187.61K-14.35K
Pretax Income-57.36M-587K-6.27M7.45M27.07M30.95M33.89M49.12M53.79M37.92M32.57M27.8M28.4M27.31M26.37M33.28M40.74M35.66M30.41M23.2M19.04M12.6M9.21M3.48M825.41K-2.83M-1.6M
Pretax Margin %-32.04%-0.26%-2.29%2.9%9.9%10.19%11.93%17.33%19.65%15.22%13.88%12.12%12.17%11.99%11.07%14.37%17.1%16.25%16.15%14.3%13.84%11.63%9.8%6.33%2.58%-28.25%-10.9%
Income Tax-73K5.68M1.19M2.31M5.97M7.03M8.04M11.38M16.51M14.11M12M10.35M10.43M10.14M9.71M12.41M14.74M12.68M10.39M8.76M6.97M4.59M3.4M222.84K00208.68K
Effective Tax Rate %0.13%-968.31%-18.99%30.96%22.06%22.72%23.73%23.17%30.69%37.19%36.85%37.21%36.72%37.14%36.83%37.28%36.18%35.56%34.16%37.75%36.63%36.44%36.9%6.4%0%0%-13.04%
Net Income-57.29M-6.27M-7.46M5.14M21.1M23.92M25.85M37.74M37.28M23.82M20.57M17.45M17.97M17.16M16.66M20.87M26M22.98M20.02M14.44M12.06M8.01M5.81M3.26M825.41K-2.83M-1.79M
Net Margin %-32%-2.76%-2.72%2%7.72%7.88%9.1%13.32%13.62%9.56%8.76%7.61%7.7%7.53%6.99%9.01%10.91%10.47%10.63%8.9%8.77%7.39%6.19%5.93%2.58%-28.25%-12.22%
Net Income Growth %-813.51%15.98%-245.21%-75.64%-11.79%-7.47%-31.5%1.23%56.53%15.81%17.84%-2.89%4.7%3.04%-20.18%-19.73%13.17%14.75%38.62%19.73%50.6%37.79%78.46%294.66%129.2%-57.54%-
Net Income (Continuing)-57.29M-6.27M-7.46M5.14M21.1M23.92M25.85M37.74M37.28M23.82M20.57M17.45M17.97M17.16M16.66M20.87M26M22.98M20.02M14.44M12.06M8.01M5.81M3.26M825.41K-2.83M-1.79M
Discontinued Operations000000000000000000000000000
Minority Interest000000000000000000000000000
EPS (Diluted)-2.74-0.30-0.370.251.041.521.291.841.821.171.020.870.900.860.800.921.140.980.820.600.500.340.250.160.04-0.28-0.28
EPS Growth %-813.33%18.92%-248%-75.96%-31.58%17.83%-29.89%1.1%55.56%14.71%17.24%-3.33%4.65%7.5%-13.04%-19.3%16.33%19.51%36.67%20%47.06%36%56.25%300%114.29%0%-
EPS (Basic)-2.74-0.30-0.370.251.051.531.291.841.831.181.020.870.900.860.810.931.150.990.830.600.510.350.300.190.05-0.28-0.28
Diluted Shares Outstanding20.92M20.6M20.4M20.34M20.36M20.12M20.05M20.49M20.43M20.38M20.25M20.14M20.04M20.05M20.71M22.64M22.75M23.48M24.3M24.27M24.21M23.83M23.69M20.75M19.74M9.94M6.37M
Basic Shares Outstanding20.92M20.6M20.4M20.27M20.18M20.06M20.04M20.46M20.35M20.23M20.12M20.02M19.9M19.93M20.61M22.51M22.62M23.31M24.09M24.11M23.66M22.86M19.47M17.3M16.36M9.94M6.37M
Dividend Payout Ratio---477.37%115.56%94.85%84.34%58.09%46.86%65.11%71.4%79.11%74.15%186.26%65.81%51.4%26.17%----------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and customer churn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Persistent Revenue Contraction Trends

As reported in recent financial filings, PETS experienced a sustained revenue decline, culminating in a 21.13% year-over-year drop, which suggests that the company's legacy transactional model is failing to retain its active customer base against more integrated, subscription-heavy e-commerce competitors in the pet pharmacy space.

The consistent quarterly revenue decay indicates that the company's value proposition is losing relevance in a market increasingly dominated by ecosystem-based platforms. Investors should monitor whether the decline in top-line performance reflects a permanent loss of market share or a temporary failure to adapt to modern digital fulfillment expectations.

Structural Margin Compression and Volatility

Based on the company's reported figures, gross margins have fluctuated significantly, reaching a low of 23.3% in 2026Q3, which highlights the company's inability to maintain pricing power or effectively manage the rising logistics costs inherent in its specialized pharmacy fulfillment model.

The volatility in gross margins suggests that the company lacks the scale to offset third-party carrier rate increases or competitive pricing pressures. This instability in core profitability implies that the business model may be structurally disadvantaged compared to larger peers with more diversified revenue streams.

Operating Leverage Decoupled from Revenue

According to the provided income statement data, operating margins have deteriorated into negative territory, reaching -17.55% as the company fails to scale its fixed overhead costs against a rapidly shrinking revenue base, signaling a breakdown in traditional operating leverage efficiency.

The inability to reduce SG&A expenses in proportion to the revenue decline suggests that the company's cost structure is increasingly rigid. This trend warrants further investigation into whether management can successfully pivot to a leaner operating model before the current cash burn exhausts available liquidity.

Earnings Quality Impaired by Losses

As indicated by the financial statements, the company has shifted from a dividend-paying entity to one reporting a -32.00% net margin, with significant quarterly volatility in net income that appears heavily influenced by non-operating items and potential restructuring charges related to recent acquisitions.

The transition to deep net losses suggests that the company's historical profitability was likely tied to a business environment that no longer exists. Investors should be wary of the quality of these earnings, as the lack of consistent positive net income makes traditional valuation metrics like P/E ratios currently inapplicable.

Liquidity Risks and Strategic Viability

Based on the reported figures, the company's cash reserves of $21.4M appear insufficient to sustain the current burn rate, which reached a significant net loss in recent quarters, suggesting that the firm may face a liquidity crunch within the next 12 to 18 months.

While some may argue that the company's pharmacy data holds strategic value for an acquirer, the current financial trajectory suggests a high risk of insolvency if the core business does not stabilize. The market appears to be pricing in a distressed scenario, reflecting the reality that the company's current cash position provides a very narrow margin for error.

PETS — Frequently Asked Questions

Quick answers to the most common questions about buying PETS stock.

What was PetMed Express, Inc.'s (PETS) revenue in 2026?

For fiscal year 2026, PetMed Express, Inc. (PETS) reported total revenue of $179.0M. This represents a 1119.7% increase compared to $14.7M in 2000.

Is PetMed Express, Inc. (PETS) profitable?

PetMed Express, Inc. (PETS) reported a net loss of $57.3M for the fiscal year ending 2026.

What is PetMed Express, Inc.'s operating profit margin?

PetMed Express, Inc. (PETS) reported an operating income of $-31.4M, resulting in an operating profit margin of -17.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is PetMed Express, Inc.'s gross profit and gross margin?

PetMed Express, Inc. (PETS) generated $50.2M in gross profit for the year, representing a gross profit margin of 28.1%. This demonstrates the company's core pricing power and production efficiency.